Category Archives: Pr Newswire

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

BERKELEY, Calif. and MAINZ, Germany, July 25, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in early detection of cancer, today announced significant improvements to its ColoAlert product, currently being commercialized across Europe and in select international markets. These updates aim to enhance customer satisfaction and streamline lab […]

Innovative Data Featuring Nanox AI Cardiac Solution Showcased at SCCT 2024

In a study conducted by Brigham & Women’s Hospital, Nanox.AI-Based Analysis helps Reveal Coronary Artery Calcium in over 50% of IMID Patients; Lead author Brittany Weber, MD, PhD, declared as ‘Young Investigator Awards’ Winner In a study conducted by Jefferson Einstein Hospital, Nanox.AI Cardiac Solution Flags CAD High-Risk Patients, Drives Significant Revenue Additional data presented by […]

Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia

Fast Track is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need Fast Track designation for Tonmya recognizes fibromyalgia as a serious condition impacting more than 10 million U.S. adults NDA submission on track for second half 2024 Tonmya has the potential to be the […]

Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024

WEST LAFAYETTE, Ind., July 25, 2024 (GLOBE NEWSWIRE) — Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 third quarter […]

Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024

THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and […]

Uxin to Report Fourth Quarter and Fiscal Year 2024 Financial Results on July 31, 2024

BEIJING, July 25, 2024 /PRNewswire/ — Uxin Limited (“Uxin” or the “Company”) (Nasdaq: UXIN), China’s leading used car retailer, today announced that it will release its financial results for the fourth quarter and fiscal year 2024 ended March 31, 2024, before the U.S. market opens on July 31, 2024. Uxin’s management team will host a conference call […]

Altair Announces Winner of the 2023-2024 Altair Global Student Contest

Luca Sutton of the TUfast Eco Team slashed 41% of weight from Shell Eco-marathon vehicle suspension with Altair® Inspire™ TROY, Mich., July 25, 2024 /PRNewswire/ — Altair (Nasdaq: ALTR), a global leader in computational intelligence, is thrilled to announce Luca Sutton, a member of the TUfast Eco Team, as the grand prize winner of the 2023-2024 Altair […]

DCG’s AI+Publishing Dazzle at the 34th HKTDC Hong Kong Book Fair

HONG KONG, July 25, 2024 /PRNewswire/ — The 34th HKTDC Hong Kong Book Fair recently commenced at the Hong Kong Convention and Exhibition Center, where DCG, a pioneer in AI+Publishing, presented its impressive range of outcomes, drawing the attention of a large audience. During the exhibition, multiple Hong Kong publishers expressed their intent to engage in […]

IASO Bio Announces NMPA Approval of IND Application for IASO-782 for Treatment of New Indication — Systemic Lupus Erythematosus (SLE)

SHANGHAI, NANJING, China and SAN JOSE, Calif.  , July 25, 2024 /PRNewswire/ — IASO Biotechnology (“IASO Bio”), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, hereby announces that the investigational new drug (IND) application for IASO-782 Injection, a fully human monoclonal antibody targeting human CD19, has been approved […]